Literature DB >> 21862943

Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.

Kaiyumars B Contractor1, Laura M Kenny, Justin Stebbing, Amarnath Challapalli, Adil Al-Nahhas, Carlo Palmieri, Sami Shousha, Jacqueline S Lewis, Katy Hogben, Quang De Nguyen, Raul Charles Coombes, Eric O Aboagye.   

Abstract

OBJECTIVE: The biological significance of [¹¹C]choline (CHO) uptake in human tumours is unclear and probably linked to choline kinase-α (CHKα) expression and cell proliferation. We directly compared CHO with [¹⁸F]fluorothymidine (FLT), an imaging biomarker of proliferation, by positron emission tomography (PET) in patients with breast cancer to investigate whether cell proliferation is an important determinant of CHO uptake. Furthermore, we evaluated CHKα and the Ki67-labelling index (LIKi67) in tumour biopsies.
METHODS: Sequential CHO-PET and FLT-PET within the same imaging session were performed in 21 patients with oestrogen receptor (ER)-positive breast cancer (28 lesions). Average and maximum CHO standardized uptake values (SUV) at 60 min: SUV60,av, and SUV60,max, and the rate constant of net irreversible uptake, Ki, were compared with FLT uptake at 60 min: SUV60,av and SUV60,max. Biopsies were stained for CHKα and LIKi67 in eight cases.
RESULTS: Tumours were equally visible on CHO-PET and FLT-PET imaging. Tumour CHO-PET strongly correlated with FLT imaging variables (Pearson's r=0.83; P<0.0001 for CHO-SUV60,max vs. FLT-SUV60,max). A statistically significant association was found between CHO-PET variables and categorical scores of cytoplasmic CHKα intensity and between FLT-PET and LIKi67 (P<0.05, one-way analysis of variance).
CONCLUSION: Choline metabolism and proliferation as assessed by PET were correlated in ER-positive breast cancer, indicating that high CHO uptake is a measure of cellular proliferation in this setting. CHO uptake was also found to be related to cytoplasmic CHKα expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862943     DOI: 10.1097/MNM.0b013e328349567b

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  10 in total

1.  Heterogeneity in stabilization phenomena in FLT PET images of canines.

Authors:  Urban Simoncic; Robert Jeraj
Journal:  Phys Med Biol       Date:  2014-11-26       Impact factor: 3.609

Review 2.  Dynamic whole-body PET imaging: principles, potentials and applications.

Authors:  Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

3.  Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.

Authors:  Sandi A Kwee; John Lim; Alex Watanabe; Kathleen Kromer-Baker; Marc N Coel
Journal:  J Nucl Med       Date:  2014-03-27       Impact factor: 10.057

4.  3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.

Authors:  Amarnath Challapalli; Tara Barwick; Rachel A Pearson; Shairoz Merchant; Francesco Mauri; Elizabeth C Howell; Katherine Sumpter; Ross J Maxwell; Eric O Aboagye; Rohini Sharma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

5.  PET Tracers for Clinical Imaging of Breast Cancer.

Authors:  Iván Peñuelas; Inés Domínguez-Prado; María J García-Velloso; Josep M Martí-Climent; Macarena Rodríguez-Fraile; Carlos Caicedo; María Sánchez-Martínez; José A Richter
Journal:  J Oncol       Date:  2012-08-29       Impact factor: 4.375

6.  Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Authors:  Maria T Grinde; Nirma Skrbo; Siver A Moestue; Einar A Rødland; Eldrid Borgan; Alexandr Kristian; Beathe Sitter; Tone F Bathen; Anne-Lise Børresen-Dale; Gunhild M Mælandsmo; Olav Engebraaten; Therese Sørlie; Elisabetta Marangoni; Ingrid S Gribbestad
Journal:  Breast Cancer Res       Date:  2014-01-21       Impact factor: 6.466

7.  Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

8.  Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.

Authors:  D K Woolf; M Beresford; S P Li; M Dowsett; B Sanghera; W L Wong; L Sonoda; S Detre; V Amin; M-L Ah-See; D Miles; A Makris
Journal:  Br J Cancer       Date:  2014-05-15       Impact factor: 7.640

Review 9.  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.

Authors:  Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.575

10.  Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis.

Authors:  Jennifer Griessinger; Julian Schwab; Qian Chen; Anna Kühn; Jonathan Cotton; Gregory Bowden; Heike Preibsch; Gerald Reischl; Leticia Quintanilla-Martinez; Hidetoshi Mori; An Nguyen Dang; Ursula Kohlhofer; Olulanu H Aina; Alexander D Borowsky; Bernd J Pichler; Robert D Cardiff; Andreas M Schmid
Journal:  NPJ Breast Cancer       Date:  2022-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.